In the current RCC therapeutic scenario, immunotherapy IT/TKI combinations may thus override the negative prognostic impact of high IL-8 levels, thereby raising the intriguing possibility that IL-8 levels help choose between immunotherapy/TKI and immunotherapy combinations. Here, CXCL8 is linked to renal cell carcinoma.